SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 06, 2020 for Shanghvi Finance Pvt Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 28, 2020 for Aditya Medisales Ltd Sun Pharma closes share buyback offer period; stock jumps 5%
The drug major is looking to expand its specialty business across different regions like Greater China and Japan after having established presence in the US market Sun Pharma bullish on specialty biz, looks to expand to new geographies
Sun Pharmaceutical Industries Managing Director Dilip Shanghvi said the company''s strategy of developing the specialty business as an additional growth engine has started delivering results SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the Listing Regulations , please find enclosed herewith the relevant extract from e-papers containing the Post Buy-back Public Announcement published in the Business Standard (Mumbai Edition - English), Business Standard - (Mumbai Edition - Hindi) and Loksatta-Jansatta - (Gujarati) Regional Language on September 26, 2020. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Closure of Buy Back
Intimation of closure of Buy-back period for buy-back of Equity Shares by Sun Pharmaceutical Industries Limited in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sun Pharma arm recalls one lot of diabetes drug Riomet ER oral in US
Sun Pharma has said it is voluntarily recalling one lot of Riomet ER oral suspension in the US market, due to the presence of a probable human carcinogen above the acceptable daily intake limit. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
This is to inform you that in compliance with the Company's Code of Conduct for prevention of Insider Trading, the window closure for trading by Designated Persons of the Company (alongwith his/her immediate relatives or any person with whom he/she shares a material financial relationship), shall be with effect from Thursday, 1st October, 2020 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2020. The date of the Board Meeting of the Company for declaration of the financial results for the quarter and half year ended 30th September, 2020 will be intimated in due course. Sun Pharma gains 2% on launching psoriasis drug in Japan
Drug major Sun Pharma on Wednesday said its Japanese subsidiary has launched its speciality product Ilumya, indicated for the treatment of plaque psor